4.2 Review

The correlation between selenium levels and autoimmune thyroid disease: a systematic review and meta-analysis

期刊

ANNALS OF PALLIATIVE MEDICINE
卷 10, 期 4, 页码 4398-4408

出版社

AME PUBL CO
DOI: 10.21037/apm-21-449

关键词

Selenium levels; selenium supplementation; autoimmune thyroid disease (AITD); meta-analysis

向作者/读者索取更多资源

Selenium supplementation was effective in treating patients with autoimmune thyroid disease, significantly reducing FT3, FT4, and TPOAb levels. There were no significant differences in TSH and TGAb levels between the experimental group and the control group.
Background: This investigation systematically evaluated the selenium levels and the effects of selenium supplementation in patients with autoimmune thyroid disease (AITD). Methods: Randomized controlled trials (RCTs) related to selenium supplementation in patients with AITD were selected from the PubMed, Medline, Web of Sciences, Embase, Cochrane Library, and Spring databases. All related literature published between January 2000 and November 2020 were included. The RCT bias risk assessment was conducted according to the Cochrane Handbook 5.0.2. The Review Manager 5.3 software was applied for meta-analysis of the included literature. Results: A total of 17 articles meeting the requirements were selected, including a total of 1,911 subjects. Meta-analysis results showed that the serum free triiodothyronine (FT3) levels in patients was greatly reduced after selenium supplementation compared to placebo treatment (MD = -0.40; 95% confidential interval (CI): -0.70-0.10; Z=2.61; P=0.009). Serum free thyroxine (FT4) levels and anti-thyroid peroxidase antibody (TPOAb) levels were also significantly reduced (MD = -0.76; 95% CI: -1.58-0.07; Z=1.79; P=0.07), and anti-thyroid peroxidase antibody (TPOAb) level was decreased observably (MD =-150.25; 95% CI: -04.06-96.43; Z=5.47; P<0.00001). The thyroid stimulating hormone (TSH) levels (MD = 0.06; 95 % CI: -0.53-0.66; Z=0.21; P=0.83) and anti-thyroglobulin antibody (TGAb) levels (MD=17.19; 95% CI: -254.86-289.25; Z=0.12; P=0.90) were not significantly different between the experimental group and the control group. Conclusions: Selenium-containing drugs were effective in treating AITD patients, and greatly reduced the levels of FT3, FT4, and TPOAb in AITD patients. These results suggested that selenium level had a great effect on AITD and selenium supplementation showed a very important effect on AITD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据